KRAS, BRAF, and PIK3CA mutations are highly concordant between primary tumors and distant metastatic CRC tumors, indicating that either type of tumor tissue could be useful as a source to detect KRAS mutations for the selection of anti-EGFR therapy [63,64]. This evidence concerns the gene EGFR and neoplasm.